CereVasc Raises $85 Million in Series C Funding for eShunt System Development

CereVasc, Inc. secured $85 million in an over-subscribed Series C financing round to support the development of its eShunt® System, a medical device designed to treat normal pressure hydrocephalus (NPH). The company intends to use the capital to advance the clinical and regulatory progress of the device, which offers a minimally invasive alternative to traditional surgical treatments for the condition.

The eShunt® System functions as an endovascular implant, allowing surgeons to treat NPH without the need for traditional, more invasive neurosurgical procedures. By utilizing this funding, CereVasc plans to expand its clinical trial operations and move toward potential regulatory milestones. The financing round attracted significant investor interest, resulting in the over-subscription of the offering. This latest infusion of capital follows the company’s ongoing efforts to establish the eShunt® System as a viable treatment option for patients suffering from the accumulation of cerebrospinal fluid in the brain.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI